2026-03-16 12:09:38
Lifecore Biomedical Reports Q4 2025 Results with $35.7M Revenue and Strategic Updates
Expected Stock impact: Noticeably Positive
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its financial results for the fourth quarter and transition period ended December 31, 2025, revealing a revenue of $35.7 million for the quarter and $75.5 million for the transition period. This marks a 10% increase in quarterly revenue compared to the same period last year, and a 20% increase for the transition period. The company attributed its growth to multiple new programs signed in the fourth quarter, including two commercial site transfer programs, bringing the total to five new programs for the transition period. CEO Paul Josephs highlighted the company's strategic initiatives aimed at improving operational efficiency and margins, with a goal of achieving a 12% revenue compound annual growth rate (CAGR) and EBITDA margins above 25% in the mid-term. Lifecore's gross profit margin for the transition period was reported at 31%, up from 26% in the previous year. The company ended the quarter with approximately $38.9 million in liquidity, including cash and revolving credit availability. Lifecore also provided guidance for 2026, expecting total revenue between $120 million and $125 million, with a net loss projected between $32.9 million and $28.9 million. The company is focused on diversifying its customer base and expanding its operational capabilities to drive future growth.
